A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study of Daikenchuto (TU-100) in Subjects With Moderate Crohn's Disease.
Phase of Trial: Phase II
Latest Information Update: 07 May 2014
At a glance
- Drugs TJ 100 (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- Sponsors Tsumura
- 10 Jun 2017 Biomarkers information updated
- 10 Mar 2014 According to the ClinicalTrials.gov record, status changed from recruiting to discontinued.
- 10 Jan 2013 Planned End Date changed from 1 Nov 2012 to 1 Aug 2013 as reported by ClinicalTrials.gov.